Opdivo 40mg Injection (Nivolumab) – Complete Product Description

Opdivo 40mg Injection (Nivolumab) is a prescription cancer immunotherapy manufactured by Bristol Myers Squibb (BMS). It contains nivolumab, a human monoclonal antibody and immune checkpoint inhibitor used in the treatment of several types of cancer.

Nivolumab works by targeting PD-1 (programmed death-1), an immune checkpoint receptor found on T cells. Certain cancer cells can use the PD-1 pathway to suppress the body’s immune response and avoid being attacked. By blocking the interaction between PD-1 and its ligands, nivolumab can help restore T-cell activity and enhance the immune system’s ability to recognize and attack cancer cells.

Opdivo may be used alone or in combination with other cancer medicines, including ipilimumab (Yervoy), chemotherapy or targeted therapies, depending on the cancer type and approved treatment regimen.

The product listed here is Opdivo 40mg Injection, manufactured by Bristol Myers Squibb, with a pack size of 1 injection/vial. It is administered by intravenous infusion under professional medical supervision.

Opdivo 40mg Injection – Product Information

Brand Name: Opdivo
Active Ingredient: Nivolumab
Strength: 40mg
Presentation: 40mg/4mL
Dosage Form: Solution for intravenous infusion
Route of Administration: Intravenous (IV) infusion
Manufacturer: Bristol Myers Squibb
Pack Size: 1 injection/vial
Drug Class: PD-1 immune checkpoint inhibitor
Therapeutic Class: Cancer immunotherapy / Antineoplastic medicine
Prescription Status: Prescription medicine

Opdivo is a specialized biological medicine and should be prepared and administered only by qualified healthcare professionals.

What Is Opdivo 40mg Injection Used For?

Opdivo (Nivolumab) is used in a variety of approved cancer treatment settings. Depending on the patient’s diagnosis, disease stage and applicable treatment protocol, Opdivo may be used for:

• Melanoma
• Non-small cell lung cancer (NSCLC)
• Renal cell carcinoma (kidney cancer)
• Classical Hodgkin lymphoma
• Head and neck squamous cell carcinoma
• Urothelial carcinoma
• Colorectal cancer with appropriate biomarkers
• Esophageal cancer
• Gastric and gastroesophageal junction cancers
• Hepatocellular carcinoma
• Mesothelioma
• Certain other approved cancers

The specific indication and treatment combination depend on factors such as cancer type, stage, biomarker status, previous treatment and overall patient health.

Opdivo for Melanoma

Opdivo is an established immunotherapy for selected patients with unresectable or metastatic melanoma.

It may be administered alone or in combination with ipilimumab, depending on the patient’s clinical circumstances.

Nivolumab helps activate the immune system by blocking PD-1 signaling, while ipilimumab targets CTLA-4. Their complementary mechanisms can provide enhanced immune activation in selected treatment regimens.

Opdivo for Non-Small Cell Lung Cancer

Nivolumab may be used for selected patients with non-small cell lung cancer (NSCLC).

Depending on the clinical setting, Opdivo may be administered alone or as part of a combination regimen involving ipilimumab and/or chemotherapy.

The appropriate treatment depends on tumor characteristics, previous treatment and the oncologist’s assessment.

Opdivo for Renal Cell Carcinoma

Opdivo is used in selected patients with advanced renal cell carcinoma.

It may be administered alone or in combination with ipilimumab or other approved treatments.

Opdivo for Classical Hodgkin Lymphoma

Nivolumab may be prescribed for selected patients with classical Hodgkin lymphoma whose disease has relapsed or progressed following previous therapies.

It works by helping restore immune activity against malignant cells.

Opdivo for Head and Neck Cancer

Opdivo may be used for certain patients with recurrent or metastatic head and neck squamous cell carcinoma after previous treatment, depending on the applicable indication.

Opdivo for Gastrointestinal and Esophageal Cancers

Nivolumab is used in selected treatment regimens for certain esophageal, gastric and gastroesophageal junction cancers.

Depending on the indication, Opdivo may be combined with chemotherapy or other immunotherapy.

How Does Opdivo (Nivolumab) Work?

Opdivo contains nivolumab, an immune checkpoint inhibitor targeting PD-1.

PD-1 is a receptor found on T cells. When PD-1 binds to its ligands, particularly PD-L1 or PD-L2, T-cell activity can be reduced.

Some cancer cells exploit this pathway to avoid immune destruction.

Nivolumab binds to PD-1 and blocks its interaction with PD-L1 and PD-L2. This removes an inhibitory signal and allows T cells to remain more active against cancer cells.

This mechanism makes Opdivo fundamentally different from traditional chemotherapy.

Opdivo 40mg Dose and Administration

Opdivo 40mg is administered through intravenous infusion.

The exact dose and treatment schedule depend on the cancer type and whether nivolumab is being used alone or in combination with other medicines.

Approved nivolumab regimens can use weight-based dosing or fixed doses, depending on the treatment indication. The 40mg vial is a strength that may be used as part of the patient’s calculated total dose.

The treating oncologist determines:

• Total dose
• Infusion schedule
• Treatment duration
• Combination medicines
• Dose adjustments or treatment interruptions

Opdivo should not be self-administered.

The infusion must be performed by a qualified healthcare professional in an appropriate clinical setting.

Common Side Effects of Opdivo 40mg

Because Opdivo activates the immune system, its side effects can differ from those associated with conventional chemotherapy.

Common adverse effects may include:

• Fatigue
• Rash
• Itching
• Diarrhea
• Nausea
• Decreased appetite
• Cough
• Shortness of breath
• Muscle pain
• Joint pain
• Fever
• Headache
• Weakness

The likelihood and severity of side effects may increase when Opdivo is administered together with other immunotherapy or anticancer medicines.

Serious Immune-Related Side Effects of Opdivo

Opdivo can cause the immune system to attack healthy organs and tissues. These immune-mediated reactions can be serious or life-threatening.

Immune-Mediated Pneumonitis

Inflammation of the lungs may occur.

Seek medical attention for:

• New or worsening cough
• Shortness of breath
• Chest pain
• Difficulty breathing

Immune-Mediated Colitis

Inflammation of the bowel can cause:

• Persistent diarrhea
• Abdominal pain
• Blood or mucus in stools
• Increased bowel frequency

Prompt medical evaluation is important if these symptoms occur.

Immune-Mediated Hepatitis

Nivolumab may cause liver inflammation.

Possible symptoms include:

• Yellowing of the skin or eyes
• Dark urine
• Abdominal discomfort
• Severe fatigue
• Loss of appetite

Liver-function tests may be performed regularly during treatment.

Immune-Mediated Endocrine Disorders

Opdivo can affect hormone-producing organs, including the:

• Thyroid gland
• Pituitary gland
• Adrenal glands
• Pancreas

Symptoms may include unusual fatigue, headaches, dizziness, changes in weight, increased thirst, frequent urination or changes in heart rate.

Immune-Mediated Nephritis

Inflammation of the kidneys can occur and may lead to changes in kidney function.

Your healthcare provider may monitor kidney-function tests during treatment.

Serious Skin Reactions

Nivolumab can cause immune-related skin reactions, including severe rash in rare cases.

Report blistering, peeling skin, severe rash or painful skin lesions immediately.

Precautions Before Using Opdivo 40mg

Before receiving Opdivo, tell your doctor if you have:

• An autoimmune disease
• A history of organ transplantation
• Lung disease
• Liver disease
• Kidney disease
• Thyroid or other endocrine problems
• Inflammatory bowel disease
• Previous severe immune-related adverse reactions
• A history of serious reactions to monoclonal antibodies

Tell your healthcare provider about all prescription medicines, supplements and other cancer treatments you are receiving.

Opdivo and Laboratory Monitoring

Patients receiving Opdivo may require regular laboratory and clinical monitoring.

Depending on the treatment regimen, healthcare professionals may monitor:

• Liver function
• Kidney function
• Thyroid function
• Blood glucose
• Blood counts
• Other hormone levels

Patients should report new or unexplained symptoms rather than waiting until the next scheduled appointment.

Opdivo During Pregnancy

Nivolumab may cause fetal harm because immune checkpoint inhibition can affect the maternal immune system and pregnancy.

Women who can become pregnant should discuss effective contraception with their healthcare provider before starting Opdivo and during the recommended period following treatment.

If pregnancy occurs while receiving Opdivo, contact your treating healthcare professional promptly.

Opdivo and Breastfeeding

It is not known with certainty whether nivolumab passes into human breast milk.

Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is generally not recommended during treatment and for the appropriate period after the final dose according to medical advice.

Patients should discuss breastfeeding with their oncologist before treatment.

Opdivo 40mg Storage

Opdivo is a biological medicine requiring controlled storage and handling.

The unopened product should be stored according to the manufacturer’s approved storage conditions and protected from light.

Do not freeze or shake Opdivo.

Preparation and dilution should be performed using appropriate sterile procedures. The prepared infusion solution should be handled according to approved pharmaceutical requirements.

Opdivo 40mg Injection Price in Pakistan

The Opdivo 40mg Injection price in Pakistan may vary depending on availability, supplier, import costs, exchange rates and current market conditions.

For the latest Opdivo 40mg price in Pakistan, customers can contact MedicineWalyDost.com to check current availability and pricing.

Because Opdivo is a specialized biological oncology medicine, prices can change. Customers should confirm the latest price before ordering.

Why Choose Opdivo 40mg Injection?

Opdivo contains nivolumab, one of the established PD-1 immune checkpoint inhibitors used in modern cancer immunotherapy.

By blocking PD-1 signaling, nivolumab can help restore T-cell activity against cancer cells in appropriately selected patients.

The Bristol Myers Squibb Opdivo 40mg Injection presentation contains 40mg of nivolumab in a 4mL solution and is supplied in a pack size of 1 injection/vial.

It is intended for intravenous administration under the supervision of an experienced healthcare professional.

Frequently Asked Questions About Opdivo 40mg

What is Opdivo 40mg Injection?

Opdivo 40mg Injection is a prescription cancer immunotherapy containing nivolumab, a monoclonal antibody that blocks the PD-1 immune checkpoint.

What is the generic name of Opdivo?

The generic name is nivolumab.

Who manufactures Opdivo 40mg Injection?

The manufacturer of the product listed here is Bristol Myers Squibb (BMS).

What is the pack size of Opdivo 40mg?

The pack size is 1 injection/vial.

How is Opdivo 40mg administered?

Opdivo is administered by intravenous infusion by a qualified healthcare professional.

What is Opdivo used for?

Opdivo is used in selected treatment regimens for cancers including melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial cancer and certain gastrointestinal cancers.

Is Opdivo chemotherapy?

No. Opdivo is an immunotherapy and PD-1 immune checkpoint inhibitor, not conventional chemotherapy.

Can Opdivo be used with Yervoy?

Yes. Nivolumab (Opdivo) and ipilimumab (Yervoy) are used together in several approved cancer treatment regimens. The dose and schedule depend on the specific cancer and treatment protocol.

What are the major risks of Opdivo?

Opdivo can cause serious immune-mediated reactions affecting organs such as the lungs, liver, bowel, kidneys, skin and endocrine glands. Prompt medical attention is important when new or worsening symptoms develop.

Does Opdivo require medical supervision?

Yes. Opdivo is a prescription biological medicine and should be prepared and administered by qualified healthcare professionals.

Can Opdivo 40mg be purchased without a prescription?

Opdivo is a specialized prescription oncology medicine and should only be used under the supervision of a qualified oncologist or healthcare professional.

Order Opdivo 40mg Injection in Pakistan

Looking for Opdivo 40mg Injection (Nivolumab) by Bristol Myers Squibb in Pakistan?

MedicineWalyDost.com provides access to specialized prescription medicines and oncology products. Contact us to check the latest Opdivo 40mg price, availability and ordering information.

Before ordering, confirm the brand, strength, active ingredient, manufacturer, pack size and prescription requirements with your doctor or pharmacist.

Order Opdivo 40mg Injection from MedicineWalyDost.com and contact us today for current availability and pricing.

Important Medical Disclaimer

Opdivo 40mg Injection is a prescription cancer immunotherapy. This product description is intended for educational and e-commerce purposes only and does not replace professional medical advice. Opdivo can cause serious or life-threatening immune-related adverse reactions and must be prescribed, prepared and administered by qualified healthcare professionals. Do not start, stop or modify treatment without consulting your treating oncologist.